R&D | May 25, 2026
Lilly brings heavy oncology firepower to ASCO with plenary data across cancers
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The approval was granted by Agenzia Italiana del Farmaco
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
Subscribe To Our Newsletter & Stay Updated
